Philips Exec: Innovation Launches Breakthrough Era For Imaging
Atul Gupta, MD and CMO of Royal Philips’ Diagnosis & Treatment business, shares his views about potential developments in imaging and wider medtech in 2026 and the value of AI. He warns that clinicians will not adopt AI they don’t trust, understand or find helpful in real-world conditions.
Medtech Insight - January 16, 2026

Executives On The Move: Eighteen CMOs, Ten CEOs, And Six CFOs Among This Week’s Changes
Recent moves in the industry include C-suite changes at Compass Therapeutics, Galecto and Archeus Technologies, plus Chordia Therapeutics gets a new CMO from Merck.
Scrip - January 16, 2026

Repaglinide Leads Roster Of UK Rises In December
In a busy month for triple-digit percentage average price rises for generics in the UK, repaglinide led the pack in December.
Generics Bulletin - January 16, 2026

J.P. Morgan: Biosimilar Vertical Integration Key Priority For Amneal In 2026
Amneal sees vertical integration of its biosimilars business, as well as global partnerships, as a key advantage to remain at the top of the game ahead of upcoming competition.
Generics Bulletin - January 16, 2026

J.P. Morgan: Viatris Outlines ‘Move Towards Real Growth In 2026’
After years of restructuring and remediation, Viatris says its base business has stabilized and it now expects cost savings, new launches and business development to drive renewed growth beginning in 2026.
Generics Bulletin - January 16, 2026

Boston Scientific’s $14.5bn Deal Folds Penumbra Thrombectomy Platforms Into Cardiovascular Franchise
Subject to shareholder approval,Boston Scientific will acquire Penumbra for approximately $11bn in cash on hand and new debt, and issue 41 million shares for the remaining $4bn.
Medtech Insight - January 16, 2026

South Africa Issues Warning About Selenium And Zinc Picolinate In Children’s Supplements
The South African Health Products Regulatory Authority is calling on manufacturers of food supplements marketed for children containing zinc picolinate and/or selenium to withdraw these products from the market within six months of the notice.
HBW Insight - January 16, 2026

DSM-Firmenich Signs Deal To Strengthen UV Filter Supply; M&A Beauty & Scent Roundup
Swiss firm DSM-Firmenich and South Korean firm ASTech sign memorandum of understanding to strengthen the firms’ global market share in UV filter ingredients. Separately, French fragrance company MANE buys Belgian biotech firm.
HBW Insight - January 16, 2026

Chinese siRNA Contenders Set For Transitions, Deals In 2026
Following Ribo Life Science’s recent Hong Kong IPO, an investor shares views with Scrip on the prospects for China's siRNA developers and likely deal trends in 2026.
Scrip - January 16, 2026

Durbin’s Supplement Registration Bill Garners CRN’s Full Support With Lighter Touch On Claims
CRN’s support, a pivot from qualified backing for the previous bill, came after the senator added language to relieve firms of some responsibility around providing all claims for their products to FDA to include public-facing list.
HBW Insight - January 16, 2026